Published in Cancer Inform on March 12, 2009
Global variation in copy number in the human genome. Nature (2006) 57.50
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics (2003) 16.60
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet (1999) 14.96
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet (1997) 12.94
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics (2004) 8.29
Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer (1997) 8.27
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet (2002) 8.19
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data. Bioinformatics (2005) 6.44
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol (2006) 5.96
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet (2001) 4.96
A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics (2005) 4.57
A statistical approach for array CGH data analysis. BMC Bioinformatics (2005) 4.05
Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A (2004) 3.82
Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet (2003) 3.27
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene (2005) 2.99
A method for calling gains and losses in array CGH data. Biostatistics (2005) 2.86
Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol (2006) 2.73
CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics (2004) 2.65
Denoising array-based comparative genomic hybridization data using wavelets. Biostatistics (2005) 2.56
Quantile smoothing of array CGH data. Bioinformatics (2004) 2.51
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle (2006) 2.37
Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res (1997) 2.14
Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res (2001) 2.07
Assessing the significance of conserved genomic aberrations using high resolution genomic microarrays. PLoS Genet (2007) 1.95
Accurate detection of aneuploidies in array CGH and gene expression microarray data. Bioinformatics (2004) 1.89
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol (2005) 1.83
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol (2005) 1.82
Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics (2006) 1.76
Modeling recurrent DNA copy number alterations in array CGH data. Bioinformatics (2007) 1.52
Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol (2005) 1.51
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol (2000) 1.47
Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer (2007) 1.43
APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci U S A (2000) 1.41
Aneuploidy and cancer: from correlation to causation. Contrib Microbiol (2006) 1.35
Debate surges over the origins of genomic defects in cancer. Science (2002) 1.32
Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene (2007) 1.31
Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene (2007) 1.13
Nucleophosmin: a versatile molecule associated with hematological malignancies. Cancer Sci (2006) 1.09
ADaCGH: A parallelized web-based application and R package for the analysis of aCGH data. PLoS One (2007) 0.99
Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosomes Cancer (2007) 0.99
Markers improve clustering of CGH data. Bioinformatics (2006) 0.94
Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer (1997) 0.93
MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Res (2007) 0.90
CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma. Anticancer Res (2004) 0.78
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Outcome signature genes in breast cancer: is there a unique set? Bioinformatics (2004) 7.96
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A (2006) 6.26
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 5.71
Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics (2004) 4.88
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol (2007) 3.53
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell (2010) 2.95
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
GeneNote: whole genome expression profiles in normal human tissues. C R Biol (2004) 2.92
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn (2008) 2.71
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle (2011) 2.46
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res (2003) 2.15
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
Alu elements contain many binding sites for transcription factors and may play a role in regulation of developmental processes. BMC Genomics (2006) 1.80
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol (2012) 1.74
Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A (2009) 1.72
Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci U S A (2004) 1.69
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol (2005) 1.60
Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol (2007) 1.54
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation. Mol Cell (2012) 1.52
Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene (2005) 1.50
Automated assignment of SCOP and CATH protein structure classifications from FSSP scores. Proteins (2002) 1.48
Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res (2007) 1.46
DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro Oncol (2012) 1.44
Wide-scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site. PLoS One (2007) 1.40
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol Cancer Ther (2011) 1.39
The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol (2009) 1.39
Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol (2013) 1.37
Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep (2005) 1.36
Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A (2013) 1.35
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol (2010) 1.32
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res (2008) 1.32
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer (2012) 1.31
Nanog transforms NIH3T3 cells and targets cell-type restricted genes. Biochem Biophys Res Commun (2006) 1.25
Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer (2006) 1.24
Prediction of chromosomal aneuploidy from gene expression data. Genes Chromosomes Cancer (2007) 1.22
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol (2012) 1.22
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One (2009) 1.19
Positional distribution of human transcription factor binding sites. Nucleic Acids Res (2008) 1.19
Design principle of gene expression used by human stem cells: implication for pluripotency. FASEB J (2004) 1.18
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J (2011) 1.17
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res (2008) 1.17
Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer (2009) 1.16
Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer. Oncogene (2003) 1.16
Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res (2006) 1.16
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
BMP-mediated inhibition of FGF signaling promotes cardiomyocyte differentiation of anterior heart field progenitors. Development (2010) 1.14
Coupled pre-mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli. Mol Syst Biol (2011) 1.13
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol (2011) 1.10
Finding motifs in promoter regions. J Comput Biol (2005) 1.09
Intensity dependent estimation of noise in microarrays improves detection of differentially expressed genes. BMC Bioinformatics (2010) 1.09
An antibody profile of systemic lupus erythematosus detected by antigen microarray. Immunology (2010) 1.08
Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol (2010) 1.08
Cluster analysis of human autoantibody reactivities in health and in type 1 diabetes mellitus: a bio-informatic approach to immune complexity. J Autoimmun (2003) 1.08
Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene (2005) 1.07
Coupled two-way clustering analysis of breast cancer and colon cancer gene expression data. Bioinformatics (2003) 1.07
Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One (2011) 1.03
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res (2010) 1.02
Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci U S A (2007) 1.02
Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res (2007) 0.99
Growth promoting signaling by tenascin-C [corrected]. Cancer Res (2004) 0.99
Vascular gene expression and phenotypic correlation during differentiation of human embryonic stem cells. Dev Dyn (2005) 0.99
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus (2006) 0.99
Coupled two-way clustering server. Bioinformatics (2003) 0.98
Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PLoS One (2011) 0.98
MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Markers (2007) 0.98
MGMT promoter methylation in malignant gliomas. Target Oncol (2010) 0.97
The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle (2013) 0.96
Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. Oncotarget (2011) 0.94
Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res (2007) 0.93
Context-specific microRNA analysis: identification of functional microRNAs and their mRNA targets. Nucleic Acids Res (2012) 0.92
Human cancers overexpress genes that are specific to a variety of normal human tissues. Proc Natl Acad Sci U S A (2005) 0.90
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro Oncol (2012) 0.90
Targeting brain-tumor stem cells. Nat Biotechnol (2007) 0.90
Potts ferromagnets on coexpressed gene networks: identifying maximally stable partitions. Phys Rev Lett (2003) 0.89
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncol (2010) 0.88
Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res (2008) 0.88
Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Prostate (2009) 0.87
Chronic rejection of a lung transplant is characterized by a profile of specific autoantibodies. Immunology (2010) 0.86
Prognostic factors for low-grade gliomas. Semin Oncol (2003) 0.85
The effect of simulated microgravity on human mesenchymal stem cells cultured in an osteogenic differentiation system: a bioinformatics study. Tissue Eng Part A (2010) 0.85